Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 5,000 Shares

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 5,000 shares of the business’s stock in a transaction dated Thursday, October 10th. The shares were sold at an average price of $8.10, for a total transaction of $40,500.00. Following the transaction, the chief executive officer now directly owns 120,695 shares in the company, valued at approximately $977,629.50. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Richard Nolan Townsend also recently made the following trade(s):

• On Tuesday, September 10th, Richard Nolan Townsend sold 5,000 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $10.65, for a total transaction of $53,250.00.
• On Monday, August 12th, Richard Nolan Townsend sold 5,000 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $11.53, for a total transaction of $57,650.00.

Lexeo Therapeutics Stock Up 2.5 %

Shares of LXEO opened at $9.15 on Thursday. The stock has a market capitalization of $301.45 million and a PE ratio of -0.41. Lexeo Therapeutics, Inc. has a 1 year low of $7.86 and a 1 year high of $22.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.38 and a current ratio of 9.38. The company’s 50-day simple moving average is $10.31 and its 200-day simple moving average is $12.86.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.64) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.64). Analysts forecast that Lexeo Therapeutics, Inc. will post -2.74 earnings per share for the current fiscal year.

Institutional Trading of Lexeo Therapeutics

Several hedge funds have recently made changes to their positions in the business. Rhumbline Advisers lifted its position in shares of Lexeo Therapeutics by 37.3% during the second quarter. Rhumbline Advisers now owns 13,357 shares of the company’s stock worth $214,000 after purchasing an additional 3,627 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Lexeo Therapeutics by 12.3% during the second quarter. Bank of New York Mellon Corp now owns 31,806 shares of the company’s stock worth $510,000 after purchasing an additional 3,483 shares in the last quarter. RA Capital Management L.P. purchased a new stake in shares of Lexeo Therapeutics during the first quarter worth approximately $10,364,000. Artal Group S.A. increased its stake in shares of Lexeo Therapeutics by 32.9% during the first quarter. Artal Group S.A. now owns 801,716 shares of the company’s stock worth $12,571,000 after buying an additional 198,281 shares during the period. Finally, Janus Henderson Group PLC increased its stake in shares of Lexeo Therapeutics by 9.0% during the first quarter. Janus Henderson Group PLC now owns 2,540,785 shares of the company’s stock worth $39,802,000 after buying an additional 210,047 shares during the period. Institutional investors and hedge funds own 60.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Chardan Capital reissued a “buy” rating and set a $23.00 price target on shares of Lexeo Therapeutics in a research report on Wednesday, August 14th. HC Wainwright decreased their target price on shares of Lexeo Therapeutics from $22.00 to $21.00 and set a “buy” rating on the stock in a research report on Tuesday, August 13th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $24.00 target price on shares of Lexeo Therapeutics in a research report on Tuesday, August 13th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Lexeo Therapeutics currently has an average rating of “Buy” and an average price target of $22.14.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.